Aurinia Pharmaceuticals Inc AUPH:NASDAQ

RT Quote | Last NASDAQ LS, VOL From CTA | USD
after hours iconAfter Hours: Last | 8:30 AM EDT
5.03quote price arrow up+0.01 (+0.20%)
Volume
1,521
Close
5.02UNCH (UNCH)
Volume
830,119
52 week range
4.71 - 12.43
Loading...
  • Open0.00
  • Day High0.00
  • Day Low0.00
  • Prev Close5.02
  • 52 Week High12.43
  • 52 Week High Date07/28/23
  • 52 Week Low4.71
  • 52 Week Low Date04/18/24

Key Stats

  • Market Cap717.957M
  • Shares Out143.02M
  • 10 Day Average Volume1.45M
  • Dividend-
  • Dividend Yield-
  • Beta1.41
  • YTD % Change-44.16

KEY STATS

  • Open0.00
  • Day High0.00
  • Day Low0.00
  • Prev Close5.02
  • 52 Week High12.43
  • 52 Week High Date07/28/23
  • 52 Week Low4.71
  • 52 Week Low Date04/18/24
  • Market Cap717.957M
  • Shares Out143.02M
  • 10 Day Average Volume1.45M
  • Dividend-
  • Dividend Yield-
  • Beta1.41
  • YTD % Change-44.16

RATIOS/PROFITABILITY

  • EPS (TTM)-0.44
  • P/E (TTM)-11.51
  • Fwd P/E (NTM)1,255.00
  • EBITDA (TTM)-52.806M
  • ROE (TTM)-16.69%
  • Revenue (TTM)191.407M
  • Gross Margin (TTM)88.78%
  • Net Margin (TTM)-32.69%
  • Debt To Equity (MRQ)22.59%

EVENTS

  • Earnings Date08/01/2024(est)
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On Aurinia Pharmaceuticals Inc

 

Profile

MORE
Aurinia Pharmaceuticals Inc. is a Canada-based fully integrated biopharmaceutical company. The Company is focused on delivering therapies to treat targeted patient populations with a high unmet medical need that are impacted by autoimmune, kidney and rare diseases. The Company has developed LUPKYNIS (voclosporin), an oral therapy for the treatment of adult patients with active lupus nephritis (LN) and continues to conduct pre-clinical, clinical, and regulatory activities to...
Daniel Billen Ph.D.
Chairman of the Board
Peter Greenleaf
President, Chief Executive Officer, Director
Joe Miller
Chief Financial Officer
Matthew Donley
Executive Vice President, Operations and Strategy
Stephen Robertson
Executive Vice President, Chief Compliance Officer, General Counsel, Corporate Secretary
Address
#140, 14315 - 118 AVENUE
Victoria, BC
T5L 4S6
Canada

Top Peers

SYMBOLLASTCHG%CHG
ABUS
Arbutus Biopharma Corp
2.89+0.01+0.35%
CYBN
Cybin Inc
0.3439-0.0186-5.131%
CRDL
Cardiol Therapeutics Inc
2.18+0.04+1.87%
MDNA
Medicenna Therapeutics Corp
2.46UNCHUNCH
DMAC
DiaMedica Therapeutics Inc
3.19+0.07+2.24%